Bioventix plc (BVXP) Ordinary 5p
Share news, reports & tips
21 October 2019 11:33
(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue...
29 March 2019 08:31
(Sharecast News) - Monoclonal antibodies developer and supplier Bioventix reported a 24% improvement in its normalised revenue in its half-year report on Friday, to £4.4m.
8 October 2018 12:09
(Sharecast News) - Aim's Bioventix announced Monday it would pay a special dividend after a strong year of revenue and profit growth - but also sounded a warning over one of its key revenue streams.
26 March 2018 08:31
(ShareCast News) - AIM-quoted pharmaceuticals company Bioventix saw revenues and profits move ahead in the first half of its trading year, leading the company to boost its first interim dividend by 20%.
16 October 2017 08:02
(ShareCast News) - Biotech group Bioventix lifted annual pre-tax profits by more than a third as revenue was boosted by a significant increase in sales of its vitamin D antibody.
4 September 2017 09:10
(ShareCast News) - Clinical antibody specialist Bioventix expects revenues and pre-tax profits to be ahead of market projections for the year after its revenue increased by almost a quarter.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.